Zenas BioPharma
ZBIO
67 hedge funds and large institutions have $257M invested in Zenas BioPharma in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 10 closing their positions.
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
3% more funds holding
Funds holding: 65 → 67 (+2)
1.89% more ownership
Funds ownership: 75.85% → 77.75% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less capital invested
Capital invested by funds: $260M → $257M (-$2.92M)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.38M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.81M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.68M |
| 4 |
EP
Eversept Partners
New York
|
+$2.14M |
| 5 |
CCM
Catalio Capital Management
New York
|
+$845K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$6.09M |
| 2 |
Morgan Stanley
New York
|
-$2.19M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.05M |
| 4 |
Millennium Management
New York
|
-$1.1M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$868K |
ZBIO Hedge Fund Activity: Q1 2025 in Review
67 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q1 2025, worth a combined $257M — down 1.1% from $260M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ZBIO positions and 10 closed out — a net gain of 2 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.38M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $6.09M sold.
- 67 institutional investors held Zenas BioPharma (ZBIO) as of Q1 2025, up from 65 in Q4 2024.
- Funds reported $257M of Zenas BioPharma stock for Q1 2025, down 1.1% quarter-over-quarter.
- 12 funds opened new Zenas BioPharma positions in Q1 2025 and 10 closed out, a net change of +2 holders.
- The largest Zenas BioPharma buyer in Q1 2025 was Fidelity Investments, an estimated $8.38M added.
- The largest Zenas BioPharma seller in Q1 2025 was Perceptive Advisors, an estimated $6.09M sold.
Based on aggregated 13F filings for Q1 2025.